Topic

SkinHealth Systems

2 essays

Saturday — May 23, 2026

Capital Markets

Tempest Therapeutics Files 8-K on Officer Departure and Compensation Changes

In clinical-stage biotech, a leadership swap is rarely just a personnel decision. The compensation terms tell you what the board believes about survival and exit.

Friday — May 22, 2026

Capital Markets

SkinHealth Systems Amends 8-K on Executive Compensation and Departures

Read essay

An amended 8-K on executive departure at a nano-cap issuer is a leading indicator of governance disruption, and possibly a capital raise.